Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinical Laboratory Management(Electronic Edition) ›› 2023, Vol. 11 ›› Issue (03): 163-166,180. doi: 10.3877/cma.j.issn.2095-5820.2023.03.007

• Investigation • Previous Articles     Next Articles

Study of CYP2C19 gene polymorphism in patients with cardiovascular and cerebrovascular diseases in Shanxi Province

Yulu Ren(), Shuning Wang, Kai Chang, Miao Yang   

  1. Taiyuan KingMed Center for Clinical Laboratory, Taiyuan Shanxi 030032, China
  • Received:2021-12-11 Online:2023-08-28 Published:2023-10-03
  • Contact: Yulu Ren

Abstract:

Objective

Study the gene polymorphism of CYP2C19 in patients with cardiovascular and cerebrovascular diseases, analyze whether it is related to age and sex differences, and provide guidance for the individualized medication of clopidogrel.

Methods

Using real-time PCR, to monitor the genotype of CYP2C19 for 776 patients with cardiovascular and cerebrovascular diseases,who were considered to receive clopidogrel antithrombotic therapy,and the correlation between age, sex and their genetic polymorphisms was analyzed.

Results

Four genotypes were detected, which were CYP2C19*1/*1 (42.14%), *2/*2 (10.82%), *3/*3 (1.03%) and *3/*17 (46.01%). The three metabolic phenotypes were extensive metabolizer/EM (42.14%), intermediata metabolizer/IM (46.01%) and poor metabolizer/PM (11.85%). The metabolic phenotypes were similar to those of related report. The CYP2C19 genotype and metabolic phenotype was associated with an increased rate of male and female patients (all P<0.05). There was no significant difference among patients of different age in CYP2C19 genotype and metabolic phenotype (all P<0.05).

Conclusions

The patients with cardiovascular and cerebrovascular diseases in Shanxi are mainly EM and IM patients, which is in line with Asian population distribution, and the number of patients with genotype CYP2C19 *1/*1 and *3/*17 is the largest. At the same time, it can not be considered to be guided according to the differences of CYP2C19 genotype, metabolic phenotype and the age, sex in drug use, still need according to the patient's own situation to give individualized medication treatment.

Key words: CYP2C19, clopidogrel, genetic polymorphism, individualized medication

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinical Laboratory Management(Electronic Edition), All Rights Reserved.
Tel: 020-81341720 Fax: 020-37103505 E-mail: clinlab@cma.org.cn
Powered by Beijing Magtech Co. Ltd